NCT02446912: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02446912 |
|---|---|
| Title | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 9, 2015 |
| Completion date | July 17, 2018 |
| Required reporting date | July 17, 2021, midnight |
| Actual reporting date | Nov. 18, 2019 |
| Date last checked at ClinicalTrials.gov | May 14, 2025 |
| Days late | None |